Evotec SE has entered into a multi-year master research collaboration and option and license agreement with Pfizer under which the companies will focus on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding...